Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Ensysce Biosciences, Inc. ENSC

Healthcare  —  Biotechnology
0.41 0.01 2.50% as of 25 Sep
Market cap
$7.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Ensysce Biosciences, Inc. (ENSC) Business Profile

Updated before January 2025

Company Overview

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotechnology company focused on addressing the opioid crisis and advancing pain management solutions. Founded in 2003, the company is headquartered in La Jolla, California. Ensysce specializes in developing innovative drug delivery systems and abuse-deterrent formulations to combat opioid misuse and addiction. The company is led by a team of experienced professionals, including Dr. Lynn Kirkpatrick, who serves as the Chief Executive Officer. Dr. Kirkpatrick brings decades of expertise in drug development and biotechnology, steering the company toward its mission of creating safer and more effective pain management therapies.

Core Business Segments

Ensysce Biosciences operates primarily in the pharmaceutical and biotechnology sectors, with a focus on the following core business segments:

Abuse-Deterrent Opioid Products

Ensysce has developed a proprietary abuse-deterrent technology platform called TAAP™ (Trypsin Activated Abuse Protection). This platform is designed to prevent the misuse of prescription opioids by making them resistant to tampering methods such as crushing, chewing, or injecting. Key products in this category include:

  • PF614: A novel abuse-deterrent extended-release oxycodone prodrug that activates only when ingested, reducing the risk of abuse.
  • PF614-MPAR™: A combination product that incorporates overdose protection by limiting the release of active ingredients in case of excessive consumption.

Overdose Protection Technology

Ensysce has also developed MPAR™ (Multi-Pill Abuse Resistance) technology, which is designed to prevent overdose by controlling the release of opioids when multiple pills are consumed. This technology is integrated into their abuse-deterrent products to enhance patient safety.

Non-Opioid Pain Management

In addition to its opioid-focused products, Ensysce is exploring non-opioid pain management solutions to provide alternative therapies for patients. These efforts align with the company’s commitment to addressing the opioid crisis comprehensively.

Business Model

Ensysce Biosciences operates on a research-driven business model, leveraging its proprietary technologies to develop innovative pharmaceutical products. The company generates revenue through licensing agreements, partnerships, and eventual commercialization of its drug candidates. By focusing on unmet medical needs in pain management and opioid abuse prevention, Ensysce aims to establish itself as a leader in the biotechnology sector. The company also collaborates with academic institutions, government agencies, and industry partners to advance its research and development efforts.

Strategic Direction

Ensysce Biosciences is committed to addressing the opioid epidemic through innovation and collaboration. The company’s strategic priorities include:

  • Advancing Clinical Trials: Ensysce is focused on progressing its lead candidates, PF614 and PF614-MPAR™, through clinical trials to achieve regulatory approval.
  • Expanding Product Portfolio: The company aims to diversify its offerings by developing non-opioid pain management solutions and exploring new therapeutic areas.
  • Sustainability Goals: Ensysce is dedicated to improving public health outcomes by reducing the societal impact of opioid misuse and addiction.
  • Global Expansion: The company plans to expand its presence in international markets by forming strategic partnerships and licensing agreements.

Competitive Landscape

Ensysce Biosciences operates in a competitive environment, facing challenges from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Purdue Pharma: Known for its opioid products, Purdue has faced significant scrutiny over its role in the opioid crisis but remains a major player in pain management.
  • Collegium Pharmaceutical: Specializes in abuse-deterrent opioid formulations and competes directly with Ensysce’s TAAP™ technology.
  • Egalet Corporation: Focuses on developing abuse-deterrent pain medications and has a portfolio of products targeting similar markets.
  • KemPharm, Inc.: Develops prodrugs for pain management and ADHD, offering competition in the abuse-deterrent space.

Risk Factors

Ensysce Biosciences faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The company’s products must undergo rigorous clinical trials and obtain FDA approval, which can be time-consuming and costly.
  • Market Dependence: Ensysce’s success is heavily reliant on the commercialization of its lead candidates, PF614 and PF614-MPAR™.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers, making it vulnerable to disruptions in the supply chain.
  • Competition: Intense competition from established pharmaceutical companies and emerging biotech firms poses a significant challenge.
  • Funding Constraints: As a clinical-stage company, Ensysce relies on external funding to support its research and development activities.

Recent Developments

Ensysce Biosciences has made significant progress in advancing its pipeline and corporate strategy:

  • Clinical Trial Milestones: The company recently announced positive results from Phase 1 clinical trials for PF614, demonstrating its safety and efficacy.
  • Partnerships: Ensysce has entered into strategic collaborations with government agencies and research institutions to accelerate the development of its abuse-deterrent technologies.
  • Regulatory Updates: The company has submitted investigational new drug (IND) applications for its lead candidates, paving the way for further clinical trials.
  • Global Developments: The ongoing opioid crisis and increased regulatory scrutiny have highlighted the need for innovative solutions like those offered by Ensysce.

Investment Considerations

Investors considering Ensysce Biosciences should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Ensysce’s proprietary TAAP™ and MPAR™ platforms position it as a leader in abuse-deterrent opioid formulations.
  • Strong Leadership: The company is led by experienced executives with a proven track record in biotechnology and drug development.
  • Market Opportunity: The growing demand for safer pain management solutions presents a significant market opportunity for Ensysce.

Risks

  • Clinical and Regulatory Risks: The success of Ensysce’s products depends on the outcome of clinical trials and regulatory approvals.
  • Financial Uncertainty: As a pre-revenue company, Ensysce relies on external funding, which may not always be readily available.
  • Competitive Pressure: The company faces intense competition from both established players and emerging biotech firms.

Conclusion

Ensysce Biosciences, Inc. is at the forefront of addressing the opioid crisis through innovative drug delivery systems and abuse-deterrent technologies. With a strong pipeline of products and a commitment to improving public health, the company is well-positioned to make a significant impact in the biotechnology sector. However, investors should carefully consider the risks associated with clinical-stage companies before making investment decisions. Looking ahead, Ensysce’s focus on innovation, strategic partnerships, and global expansion provides a promising outlook for future growth.